US 12,269,823 B2
Crystal form of pyridopyrimidine derivative and preparation method thereof
Qi Wu, Jiangsu (CN); Zhenxing Du, Jiangsu (CN); Jie Wang, Jiangsu (CN); Lin Wang, Jiangsu (CN); Weidong Lu, Shanghai (CN); Qiyun Shao, Shanghai (CN); Jun Feng, Shanghai (CN); and Feng He, Shanghai (CN)
Assigned to Jiangsu Hengrui Medicine Co., Ltd., Jiangsu (CN); and Shanghai Hengrui Pharmaceutical Co., Ltd., Shanghai (CN)
Appl. No. 17/757,946
Filed by JIANGSU HENGRUI MEDICINE CO., LTD., Jiangsu (CN); and SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD., Shanghai (CN)
PCT Filed Dec. 31, 2020, PCT No. PCT/CN2020/142037
§ 371(c)(1), (2) Date Jun. 24, 2022,
PCT Pub. No. WO2021/136488, PCT Pub. Date Jul. 8, 2021.
Claims priority of application No. 202010002822.9 (CN), filed on Jan. 2, 2020.
Prior Publication US 2023/0058425 A1, Feb. 23, 2023
Int. Cl. C07D 471/04 (2006.01)
CPC C07D 471/04 (2013.01) [C07B 2200/13 (2013.01)] 17 Claims
 
1. A crystalline form of a compound of formula (I):

OG Complex Work Unit Chemistry
selected from the group consisting of crystalline form A and crystalline form B, wherein:
the crystalline form A has an X-ray powder diffraction pattern with characteristic peaks at 2θ angles of 8.610, 9.740, 13.903, 15.313, 16.354, 17.675, 17.879, 19.184, 19.905, 20.901, 21.365, 22.319 and 23.057; and
the crystalline form B has an X-ray powder diffraction pattern with characteristic peaks at 2θ angles of 4.60, 8.77, 9.90, 13.86, 15.45, 16.44, 17.74, 18.03, 19.31, 19.91, 21.07, 21.52, 22.48 and 23.22.